• Home
  • Media Events
  • Guest Lecture on Future Prospects in Biomedical Engineering Focusing On 3D Printing and Cancer Therapy

Guest Lecture on Future Prospects in Biomedical Engineering Focusing On 3D Printing and Cancer Therapy

Published on: March 21, 2025

Guest Lecture on Future Prospects in Biomedical Engineering with Focus on 3D Printing and Cancer Therapy

On 21st March 2025, the Department of Clinical Research, Himalayan Institute of Medical Sciences, in collaboration with the Himalayan School of Biosciences at Swami Ram Himalayan University, organized an insightful guest lecture titled “Future Prospects in Biomedical Engineering: Focusing on 3D Printing and Cancer Therapy.” The event took place at the Vishweshariya Auditorium, Himalayan School of Science and Technology, and was attended by 152 participants including undergraduate and postgraduate students, faculty members, and researchers.

The lecture was delivered by Prof. Dr. Amit Mehndiratta, Associate Professor at the Center for Biomedical Engineering, IIT Delhi, and a member of the University Research Advisory Board at SRHU. Dr. Amit shared his expert knowledge on the latest advancements in 3D printing technology and its transformative applications in the field of cancer therapy.

Dr. Mehndiratta began by introducing the fundamentals of 3D printing and its evolution within biomedical engineering. He highlighted the use of 3D printing in creating customized prosthetics, implants, and tissue engineering solutions. Special emphasis was placed on bioprinting—the process of fabricating artificial organs and tissues, which holds great promise for transplantation therapies. Challenges such as material compatibility, durability, and regulatory hurdles were also discussed.

A significant part of the lecture focused on how 3D printing is revolutionizing cancer treatment. Dr. Amit explained the development of patient-specific tumor models that allow for personalized treatment approaches. He described innovative 3D-printed drug delivery systems designed to target cancer cells more precisely, minimizing side effects. Additionally, the role of 3D printing in surgical planning and precision oncology was elaborated upon, along with emerging research on 3D-printed scaffolds to help regenerate tissues damaged by cancer.

Looking ahead, the lecture covered exciting future prospects, including 4D bioprinting—where printed structures can change over time—and the integration of artificial intelligence and machine learning to optimize 3D-printed biomedical solutions. Ethical considerations and regulatory challenges in adopting these new technologies were also discussed, emphasizing the need for careful implementation.

The session concluded with an interactive Q&A, where students and faculty engaged actively with Dr. Mehndiratta, posing questions on the practical feasibility of 3D-printed organs and the ethics of bioprinting in cancer research. The lecture received highly positive feedback for making complex scientific topics accessible and relevant.

The event was formally closed with a vote of thanks by Dr. Sanjay Gupta, Principal of the Himalayan School of Biosciences, who expressed gratitude to Dr. Amit Mehndiratta for his valuable insights and time.

This guest lecture enriched participants’ understanding of how biomedical engineering and 3D printing are shaping the future of cancer therapy, bridging academic knowledge with cutting-edge industry developments.

Picture1
Picture2
   Admissions Form         

Admission Open For 2025

×
International Endowed Chair Professor

Prof Rakesh Kumar

Prof Rakesh Kumar is the Founder and President of the Breast Cancer in Young Women Foundation (USA), dedicated to vaddressing the distinct issues affecting young women with breast cancer. He also serves as the International Endowed Chair Professor at the Cancer Research Institute of the Himalayan Institute of Medical Sciences. Additionally, he holds adjunct professorships at Rutgers New Jersey Medical School and Virginia Commonwealth University.

Dr Kumar earned his Ph.D. from the All India Institute of Medical Sciences in 1984 and began his research career at Memorial Sloan Kettering Cancer Center in January 1986. From 1988 to 2017, he held various academic and leadership positions —including faculty member, tenured professor, distinguished professor, endowed chair, department chair, and research leader—at esteemed institutions such as Memorial Sloan Kettering Cancer Center in New York and the University of Texas MD Anderson Cancer Center in Houston. From 2017 to 2022, he served as the National Chair for Cancer Research for the Government of India and as a distinguished professor, continuing his innovative work in breast cancer research.

With nearly 40 years of research and professional experience, Dr. Kumar has made conceptual contributions to the field of cancer research (h-index 108, citations >50,000). He has authored over 325 peer-reviewed publications, edited or co-edited nine books, and delivered 290 invited lectures worldwide. His work has been featured on the covers of 18 major cancer journals and has been highlighted in institutional research reports of the MD Anderson Cancer Center.

A passionate educator and mentor, Dr. Kumar has guided 67 trainees throughout his career. He serves on the editorial boards of multiple leading cancer journals and has served on the editorial boards of 21 top cancer journals. His global reputation is further demonstrated by his participation in about 100 peer-review panels for cancer research funding in the US and internationally over the past 28 years.

Dr. Kumar's innovative research has earned him numerous prestigious honors, including the Hinkle Society Faculty Award at Penn State University (1994), the Dalla/Fort Worth Living Legend Faculty Achievement Award in Basic Sciences (2004), the Ranbaxy Research Award (2006), and the Lifetime Achievement Award from the American Association of Indian Scientists in Cancer Research (2013), among others. Dr. Kumar's pioneering research continues to have a profound influence on the fields of oncology and breast cancer, opening up new opportunities for biomedical scientists and trainees worldwide.